WSTAM
ATRS

Wilbanks Smith & Thomas Asset Management’s Antares Pharma, Inc. ATRS Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50,000
Closed -$168K – 1430
2018
Q3 		$168K Buy
+50,000
New +$154K 0.01% 428

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ATRS Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Antares Pharma, Inc. (ATRS) in Q4 2018, closing a stake of 50,000 shares — an estimated $168K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ATRS in Q3 2018 and held it in 1 quarter. The position peaked at $168K in Q3 2018. 120 funds tracked by Wall St. Rank hold ATRS as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Antares Pharma, Inc. position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 50,000 Antares Pharma, Inc. shares in Q4 2018, an estimated $168K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Antares Pharma, Inc. in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Antares Pharma, Inc. position peaked at $168K in Q3 2018.
  • 120 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.